Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 6
2006 2
2007 2
2008 3
2015 2
2017 2
2019 1
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A+CD141+ cDC1 and CD14+ antigen-presenting cell recruitment.
Koster BD, López González M, van den Hout MF, Turksma AW, Sluijter BJ, Molenkamp BG, van Leeuwen PA, Vosslamber S, Scheper RJ, van den Eertwegh AJ, van den Tol MP, Jordanova EJ, de Gruijl TD. Koster BD, et al. Among authors: molenkamp bg. J Immunother Cancer. 2021 Mar;9(3):e001962. doi: 10.1136/jitc-2020-001962. J Immunother Cancer. 2021. PMID: 33737341 Free PMC article.
In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma.
Koster BD, de Jong TD, van den Hout MFCM, Sluijter BJR, Vuylsteke RJCLM, Molenkamp BG, Vosslamber S, van den Tol MP, van den Eertwegh AJM, de Gruijl TD. Koster BD, et al. Among authors: molenkamp bg. Oncoimmunology. 2019 Dec 26;9(1):1708066. doi: 10.1080/2162402X.2019.1708066. eCollection 2020. Oncoimmunology. 2019. PMID: 32002303 Free PMC article.
Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence.
van den Hout MFCM, Koster BD, Sluijter BJR, Molenkamp BG, van de Ven R, van den Eertwegh AJM, Scheper RJ, van Leeuwen PAM, van den Tol MP, de Gruijl TD. van den Hout MFCM, et al. Among authors: molenkamp bg. Cancer Immunol Res. 2017 Nov;5(11):969-977. doi: 10.1158/2326-6066.CIR-17-0110. Epub 2017 Sep 21. Cancer Immunol Res. 2017. PMID: 28935649
Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, van den Eertwegh AJM, de Gruijl TD. Koster BD, et al. Among authors: molenkamp bg. Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944. Clin Cancer Res. 2017. PMID: 28972083 Clinical Trial.
Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.
Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD. Sluijter BJ, et al. Among authors: molenkamp bg. Cancer Immunol Res. 2015 May;3(5):495-505. doi: 10.1158/2326-6066.CIR-14-0165. Epub 2015 Jan 29. Cancer Immunol Res. 2015. PMID: 25633713 Clinical Trial.
21 results